Philipp Rathert, was successful in securing research funding from the German Cancer Aid. The grant will support a project exploring epigenetic resistance mechanisms in ovarian cancer (OC). The Project is a collaboration with the Department of Obstetrics and Gynecology, University Hospital Munich (LMU).
Misregulation of the epigenome is a feature of many different diseases, especially cancer. Philipp Rathert, group leader at the IBC, is interested in the functional characterization of chromatin regulatory networks and their influence of resistance mechanisms in standard cancer treatments. Advances in our ability to characterize the dynamics and wiring of chromatin regulators, as well as the induced transcriptional output under different conditions, will substantially enhance our understanding of the dynamics of gene regulation. Therefore, the group of Philipp Rathert combines state-of-the-art functional genetic tools (RNAi or CRISPR/Cas9) with cell biology and biochemical assays.
Deutsche Krebshilfe (German Cancer Aid) is Germany’s leading non-governmental funding and non-profit-making organization of oncology-related activities. Fundamentally, all the projects supported are driven by high levels of scientific quality and the potential for significant clinical impact, so that cancer patients rapidly benefit from new knowledge.